After receiving FDA breakthrough therapy status for its lead candidate in July, gene therapy company AveXis has released promising new safety and efficacy data. AVXS-101 is being developed to ...
At the time, Novartis’ AveXis unit – which developed Zolgensma – said the questions raised by the regulators weren’t related to a data manipulation scandal that emerged with the therapy ...
M.D., Ph.D. AveXis, Inc., a Novartis company, licensed REGENXBIO's NAV adeno-associated virus 9 (AAV9) vector in 2014 and entered into an expanded license for rights to the entire NAV Technology ...
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
aMedical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil bGrupo de Pesquisa Clínica em Genética Médica, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil ...
DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback